Study on the effect and mechanism of ATAD3A on the immune evasion of triple-negative breast cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100047916

Enrollment

Unknown

Registered

2021-06-27

Start date

2021-07-01

Completion date

Unknown

Last updated

2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

case series:none

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The images were re-read by more than 2 pathologists and the diagnosis of breast cancer was confirmed.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Expression of ATAD3A;	—

Countries

China

Contacts

Public ContactYang Yi

the First Affiliated Hospital of Army Medical University, PLA

17618835@qq.com+86 15021130563

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026